Publications

2020

Rombach, I., Iftikhar, M., Jhuti, G.S. et al. “Obtaining EQ-5D-5L utilities from the disease specific quality of life Alzheimer’s disease scale: development and results from a mapping study.” Quality of Life Research.

Hansson-Hedblom, A., Axelsson, I., Jacobson, L., Tedroff, J., & Borgström, F. (2020). “Economic consequences of migraine in Sweden and implications for the cost-effectiveness of onabotulinumtoxinA (Botox) for chronic migraine in Sweden and Norway.” The journal of headache and pain, 21(1), 99.

Geale K, Henriksson M, Jokinen J, Schmitt-Egenolf M. “Association of Skin Psoriasis and Somatic Comorbidity With the Development of Psychiatric Illness in a Nationwide Swedish Study.” JAMA Dermatol. Published online June 03, 2020.

Banefelt, J., Lindh, M., Svensson, M. K., Eliasson, B., & Tai, M. (2020). “Statin Dose Titration Patterns and Subsequent Major Cardiovascular Events in very High-Risk Patients – Estimates from Swedish Population-based Registry Data.” European heart journal. Quality of care & clinical outcomes , qcaa023.

Borgström, F., Karlsson, L., Ortsäter, G., Norton, N., Halbout, P., Cooper, C., Lorentzon, M., McCloskey, E. V., Harvey, N. C., Javaid, M. K., Kanis, J. A., & International Osteoporosis Foundation (2020). “Fragility fractures in Europe: burden, management and opportunities.” Archives of osteoporosis, 15(1), 59.

Banefelt, J., M. Lindh, M. K. Svensson, B. Eliasson and M. Tai (2020). “Statin Dose Titration Patterns and Subsequent Major Cardiovascular Events in very High-Risk Patients – Estimates from Swedish Population-based Registry Data.” Eur Heart J Qual Care Clin Outcomes.

Geale, K., H. Darabi, M. Lindh, H. Fues Wahl, O. Strom, H. Cao, L. Alvares, R. Dodge, E. Loefroth, A. Altraja, V. Backer, H. Backman, L. Bjermer, A. Bossios, B. Bogvald Aarli, B. Dahlen, O. Hilberg, C. Janson, H. Kankaanranta, J. Karjalainen, P. Kauppi, M. Kilpelainen, S. Lehmann, L. Lehtimaki, B. Lundback, T. Sandstrom, C. S. Ulrik, A. Sverrild, A. Viinanen, A. von Bulow, V. Yasinska and C. Porsbjerg (2020). “NORDSTAR: paving the way for a new era in asthma research.” Eur Respir J 55(4).

Janssen, O., S. J. B. Vos, G. Garcia-Negredo, C. Tochel, A. Gustavsson, M. Smith, A. Ly, M. Nelson, H. Baldwin, C. Sudlow, C. Bexelius, C. Jindra, N. Vaci, S. Bauermeister, J. Gallacher, A. Ponjoan, C. Dufouil, J. Garre Olmo, L. Pedersen, I. Skoog, A. Hottgenroth, P. J. Visser, J. van der Lei and C. Diaz (2020). “Real-world evidence in Alzheimer’s disease: The ROADMAP Data Cube.” Alzheimers Dement 16(3): 461-471.

Soreskog, E., F. Borgstrom, L. Shepstone, S. Clarke, C. Cooper, I. Harvey, N. C. Harvey, A. Howe, H. Johansson, T. Marshall, T. W. O’Neill, T. J. Peters, N. M. Redmond, D. Turner, R. Holland, E. McCloskey, J. A. Kanis and S. s. team (2020). “Long-term cost-effectiveness of screening for fracture risk in a UK primary care setting: the SCOOP study.” Osteoporos Int.

Soreskog, E., O. Strom, A. Spangeus, K. E. Akesson, F. Borgstrom, J. Banefelt, E. Toth, C. Libanati and M. Charokopou (2020). “Risk of major osteoporotic fracture after first, second and third fracture in Swedish women aged 50years and older.” Bone 134: 115286.

Strom, O., R. Lauppe, O. Ljunggren, A. Spangeus, G. Ortsater, J. O’Kelly and K. Akesson (2020). “Real-world effectiveness of osteoporosis treatment in the oldest old.” Osteoporos Int.

Toth, E., J. Banefelt, K. Akesson, A. Spangeus, G. Ortsater and C. Libanati (2020). “History of Previous Fracture and Imminent Fracture Risk in Swedish Women Aged 55 to 90 Years Presenting With a Fragility Fracture.” J Bone Miner Res.

Widen, J., M. Ivarsson, L. Schalin, P. Vrouchou, M. Schwenkglenks, O. Heimburger, Z. Ademi and C. S. Sutherland (2020). “Cost-Effectiveness Analysis of Patiromer in Combination with Renin-Angiotensin-Aldosterone System Inhibitors for Chronic Kidney Disease in Sweden.” Pharmacoeconomics.

2019

Green, C., R. Handels, A. Gustavsson, A. Wimo, B. Winblad, A. Skoldunger and L. Jonsson (2019). “Assessing cost-effectiveness of early intervention in Alzheimer’s disease: An open-source modeling framework.” Alzheimers Dement.

Hansson-Hedblom, A., E. Jonsson, P. Fritzell, O. Hagg and F. Borgstrom (2019). “The Association Between Patient Reported Outcomes of Spinal Surgery and Societal Costs: A Register Based Study.” Spine (Phila Pa 1976) 44(18): 1309-1317.

Iderberg H, Willers C, Borgstrom F, Hedlund R, Hagg O, Moller H, et al. “Predicting clinical outcome and length of sick leave after surgery for lumbar spinal stenosis in Sweden: a multi-register evaluation.” Eur Spine J. 2019;28(6):1423-32.

Kanis JA, Johansson H, Harvey NC, Lorentzon M, Liu E, Borgstrom F, et al. “Correspondence in response to OSIN-D-18-00831 quantifying imminent risk.” Osteoporos Int. 2019;30(2):525-6.

Ortsater G, Borgstrom F, Soulard S, Miltenburger C. A “Budget Impact Model to Estimate the Environmental Impact of Adopting RESPIMAT((R)) Re-usable in the Nordics and Benelux.” Adv Ther. 2019.

Tatangelo G, Watts J, Lim K, Connaughton C, Abimanyi-Ochom J, Borgstrom F, et al. “The Cost of Osteoporosis, Osteopenia, and Associated Fractures in Australia in 2017.” J Bone Miner Res. 2019;34(4):616-25.

Tochel C, Smith M, Baldwin H, Gustavsson A, Ly A, Bexelius C, et al. “What outcomes are important to patients with mild cognitive impairment or Alzheimer’s disease, their caregivers, and health-care professionals? A systematic review.” Alzheimers Dement (Amst).

Lauppe R, Akesson KE, Ljunggren O, Spangeus A, Ortsater G, Feudjo-Tepie M and Strom, O. Differing impact of clinical factors on the risk of fracture in younger and older women in the general population and an osteoporosis clinic population. Arch Osteoporos.

Lindh, M., J. Banefelt, K-M. Fox, S. Hallberg, M-H. Tai, M. Eriksson, G. Villa, M-K. Svensson, and Y. Qian (2019). “Cardiovascular event rates in a high atherosclerotic cardiovascular disease risk population–estimates from Swedish population-based register data.” European Heart Journal – Quality of Care and Clinical Outcomes.

Grip, E. T., Svensson, A. M., Miftaraj, M., Eliasson, B., Franzén, S., Gudbjörnsdottir, S., & Carlsson, K. S. (2019). Real-World Costs of Continuous Insulin Pump Therapy and Multiple Daily Injections for Type 1 Diabetes: A Population-Based and Propensity-Matched Cohort From the Swedish National Diabetes Register. Diabetes care42(4), 545-552.

Banefelt, J., K-E. Åkesson, A. Spångéus, O. Ljunggren, L. Karlsson, O. Ström, G. Ortsäter, C. Libanati, and E. Toth (2019). “Risk of imminent fracture following a previous fracture in a Swedish database study.” Osteoporosis International.

2018

Rudberg, A-S., E. Berge, A. Gustavsson, P. Näsman, and E. Lundström (2018). “Long-term health-related quality of life, survival and costs by different levels of functional outcome six months after stroke.” European Stroke Journal.

Guirant, L., F. Carlos, D. Curiel, J. A. Kanis, F. Borgstrom, A. Svedbom and P. Clark (2018). “Health-related quality of life during the first year after a hip fracture: results of the Mexican arm of the International Cost and Utility Related to Osteoporotic Fractures Study (MexICUROS).” Osteoporos Int 29(5): 1147-1154.

Hansson-Hedblom, A., C. Almond, F. Borgstrom, I. Sly, D. Enkusson, A. Troelsgaard Buchholt and L. Karlsson (2018). “Cost-effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden.” Cost Eff Resour Alloc 16: 28.

Jonsson, E., A. Hansson-Hedblom, O. Ljunggren, K. Akesson, A. Spangeus, J. A. Kanis and F. Borgstrom (2018). “A health economic simulation model for the clinical management of osteoporosis.” Osteoporos Int 29(3): 545-555.

Kanis, J. A., H. Johansson, A. Oden, N. C. Harvey, V. Gudnason, K. M. Sanders, G. Sigurdsson, K. Siggeirsdottir, L. A. Fitzpatrick, F. Borgstrom and E. V. McCloskey (2018). “Characteristics of recurrent fractures.” Osteoporos Int 29(8): 1747-1757.

Luthman, S., J. Widen and F. Borgstrom (2018). “Appropriateness criteria for treatment of osteoporotic vertebral compression fractures.” Osteoporos Int 29(4): 793-804.

Olafsson, G., E. Jonsson, P. Fritzell, O. Hagg and F. Borgstrom (2018). “Cost of low back pain: results from a national register study in Sweden.” Eur Spine J.

Svedbom, A., F. Borgstrom, E. Hernlund, O. Strom, V. Alekna, M. L. Bianchi, P. Clark, M. D. Curiel, H. P. Dimai, M. Jurisson, A. Uuskula, M. Lember, R. Kallikorm, O. Lesnyak, E. McCloskey, O. Ershova, K. M. Sanders, S. Silverman, M. Tamulaitiene, T. Thomas, A. N. A. Tosteson, B. Jonsson and J. A. Kanis (2018). “Quality of life after hip, vertebral, and distal forearm fragility fractures measured using the EQ-5D-3L, EQ-VAS, and time-trade-off: results from the ICUROS.” Qual Life Res 27(3): 707-716.

2017

Eriksson, D., L. Karlsson, O. Eklund, H. Dieperink, E. Honkanen, J. Melin, K. Selvig and J. Lundberg (2017). “Real-world costs of autosomal dominant polycystic kidney disease in the Nordics.” BMC Health Serv Res 17(1): 560.

Gustavsson, A., C. Green, R. W. Jones, H. Forstl, D. Simsek, F. de Reydet de Vulpillieres, S. Luthman, N. Adlard, S. Bhattacharyya and A. Wimo (2017). “Current issues and future research priorities for health economic modelling across the full continuum of Alzheimer’s disease.” Alzheimers Dement 13(3): 312-321.

Jonsson, E., G. Olafsson, P. Fritzell, O. Hagg and F. Borgstrom (2017). “Profile of Low Back Pain: Treatment and Costs Associated With Patients Referred to Orthopaedic Specialists in Sweden.” Spine (Phila Pa 1976).

Karlsson, L., J. Mesterton, M. F. Tepie, M. Intorcia, J. Overbeek and O. Strom (2017). “Exploring methods for comparing the real-world effectiveness of treatments for osteoporosis: adjusted direct comparisons versus using patients as their own control.” Arch Osteoporos 12(1): 81.

Olafsson, G., E. Jonsson, P. Fritzell, O. Hagg and F. Borgstrom (2017). “A health economic lifetime treatment pathway model for low back pain in Sweden.” J Med Econ: 1-18.

Svedbom, A., F. Borgstom, E. Hernlund, O. Strom, V. Alekna, M. L. Bianchi, P. Clark, M. D. Curiel, H. P. Dimai, M. Jurisson, R. Kallikorm, M. Lember, O. Lesnyak, E. McCloskey, K. M. Sanders, S. Silverman, A. Solodovnikov, M. Tamulaitiene, T. Thomas, N. Toroptsova, A. Uuskula, A. N. A. Tosteson, B. Jonsson and J. A. Kanis (2017). “Quality of life for up to 18 months after low-energy hip, vertebral, and distal forearm fractures-results from the ICUROS.” Osteoporos Int.

Svedbom, A., F. Borgstrom, E. Hernlund, O. Strom, V. Alekna, M. L. Bianchi, P. Clark, M. D. Curiel, H. P. Dimai, M. Jurisson, A. Uuskula, M. Lember, R. Kallikorm, O. Lesnyak, E. McCloskey, O. Ershova, K. M. Sanders, S. Silverman, M. Tamulaitiene, T. Thomas, A. N. A. Tosteson, B. Jonsson and J. A. Kanis (2017). “Quality of life after hip, vertebral, and distal forearm fragility fractures measured using the EQ-5D-3L, EQ-VAS, and time-trade-off: results from the ICUROS.” Qual Life Res.

2016

Banefelt, J., S. Hallberg, K. M. Fox, J. Mesterton, C. J. Paoli, G. Johansson, L. A. Levin, P. Sobocki and S. R. Gandra (2016). “Work productivity loss and indirect costs associated with new cardiovascular events in high-risk patients with hyperlipidemia: estimates from population-based register data in Sweden.” Eur J Health Econ 17(9): 1117-1124.

Bergqvist, J., H. Iderberg, J. Mesterton, N. Bengtsson, B. Wettermark and R. Henriksson (2016). “Healthcare resource use, comorbidity, treatment and clinical outcomes for patients with primary intracranial tumors: a Swedish population-based register study.” Acta Oncol: 1-10.

Darabi, H., J. Beesley, A. Droit, S. Kar, S. Nord, M. Moradi Marjaneh, P. Soucy, K. Michailidou, M. Ghoussaini, H. Fues Wahl et al., and A. M. Dunning (2016). “Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs).” Sci Rep 6: 32512.

Eklund, O., F. Afzal, F. Borgstrom, J. Flavin, A. Ternouth, M. E. Ojanguren, C. Crespo and M. Baldwin (2016). “Cost-effectiveness of tiotropium versus glycopyrronium in moderate to very severe chronic obstructive pulmonary disease in Canada, Spain, Sweden, and the UK.” Clinicoecon Outcomes Res 8: 243-252.

Eriksson, D., D. Goldsmith, S. Teitsson, J. Jackson and F. van Nooten (2016). “Cross-sectional survey in CKD patients across Europe describing the association between quality of life and anaemia.” BMC Nephrol 17(1): 97.

Eriksson, D., L. Karlsson, O. Eklund, H. Dieperink, E. Honkanen, J. Melin, K. Selvig and J. Lundberg (2016). “Health-related quality of life across all stages of autosomal dominant polycystic kidney disease.” Nephrol Dial Transplant.

Hallberg, S., J. Banefelt, K. M. Fox, J. Mesterton, G. Johansson, L. A. Levin, P. Sobocki and S. R. Gandra (2016). “Lipid-lowering treatment patterns in patients with new cardiovascular events – estimates from population-based register data in Sweden.” Int J Clin Pract 70(3): 222-228.

Hallberg, S., S. R. Gandra, K. M. Fox, J. Mesterton, J. Banefelt, G. Johansson, L. A. Levin and P. Sobocki (2016). “Healthcare costs associated with cardiovascular events in patients with hyperlipidemia or prior cardiovascular events: estimates from Swedish population-based register data.” Eur J Health Econ 17(5): 591-601.

Jurisson, M., H. Pisarev, J. Kanis, F. Borgstrom, A. Svedbom, R. Kallikorm, M. Lember and A. Uuskula (2016). “Quality of life, resource use, and costs related to hip fracture in Estonia.” Osteoporos Int 27(8): 2555-2566.

Marques, A., O. Lourenco, G. Ortsater, F. Borgstrom, J. A. Kanis and J. A. da Silva (2016). “Cost-Effectiveness of Intervention Thresholds for the Treatment of Osteoporosis Based on FRAX(R) in Portugal.” Calcif Tissue Int.

Mesterton, J., P. Lindgren, A. Ekenberg Abreu, L. Ladfors, M. Lilja, S. Saltvedt and I. Amer-Wahlin (2016). “Case mix adjustment of health outcomes, resource use and process indicators in childbirth care: a register-based study.” BMC Pregnancy Childbirth 16(1): 125.

Wimo, A., L. Jonsson, L. Fratiglioni, P. O. Sandman, A. Gustavsson, A. Skoldunger and L. Johansson (2016). “The societal costs of dementia in Sweden 2012 – relevance and methodological challenges in valuing informal care.” Alzheimers Res Ther 8(1): 59.

Wohlin, J., H. Stalberg, O. Ström, O. Rolfson, C. Willers and M. Brommels (2016). Effects of introducing bundled payment and patients’ choice of provider for elective hip and knee replacements in Stockholm county. public report. http://www.sll.se/verksamhet/halsa-och-vard/nyheter-halsa-och-vard/2016/11/Ny-modell-forbattrar-varden-for-hoft–och-knapatienter/, Department of Learning, Informatics, Management and Ethics.

2015

Abimanyi-Ochom, J., J. J. Watts, F. Borgstrom, G. C. Nicholson, C. Shore-Lorenti, A. L. Stuart, Y. Zhang, S. Iuliano, E. Seeman, R. Prince, L. March, M. Cross, T. Winzenberg, L. L. Laslett, G. Duque, P. R. Ebeling and K. M. Sanders (2015). “Changes in quality of life associated with fragility fractures: Australian arm of the International Cost and Utility Related to Osteoporotic Fractures Study (AusICUROS).” Osteoporos Int 26(6): 1781-1790.

Banefelt, J., S. Hallberg, K. M. Fox, J. Mesterton, C. J. Paoli, G. Johansson, L. A. Levin, P. Sobocki and S. R. Gandra (2015). “Work productivity loss and indirect costs associated with new cardiovascular events in high-risk patients with hyperlipidemia: estimates from population-based register data in Sweden.” Eur J Health Econ.

Borgstrom, F., D. P. Beall, S. Berven, S. Boonen, S. Christie, D. F. Kallmes, J. A. Kanis, G. Olafsson, A. J. Singer and K. Akesson (2015). “Health economic aspects of vertebral augmentation procedures.” Osteoporos Int 26(4): 1239-1249.

Eklund, O., F. Afzal and F. Borgstrom (2015). “Cost-effectiveness of tiotropium versus usual care and glycopyrronium in the treatment of chronic obstructive pulmonary disease in Sweden.” Cost Eff Resour Alloc 13: 13.

Eklund, O., F. Afzal, F. Borgstrom, M. E. Ojanguren, C. Crespo and M. Baldwin (2015). “Cost-Effectiveness Of Tiotropium Vs Glycopyrronium In Moderate To Very Severe Copd In Spain.” Value Health 18(7): A501.

Eriksson, D., L. Karlsson, O. Eklund, H. Dieperink, E. Honkanen, J. Melin, K. Selvig and J. Lundberg (2015). “Autosomal Polycystic Kidney Disease (Adpkd): Costs And Resource Utilisation In The Nordic Countries.” Value Health 18(7): A513.

Jonsson, E., D. Eriksson, K. Akesson, O. Ljunggren, S. Salomonsson, F. Borgstrom and O. Strom (2015). “Swedish osteoporosis care.” Arch Osteoporos 10: 222.

Jonsson, E., G. Olafsson, P. Fritzell, O. Hagg and F. Borgstrom (2015). “Productivity Loss Due to Low Back Pain: Results from Swedish Registers.” Value Health 18(7): A649.

Karlsson, L., J. Lundkvist, E. Psachoulia, M. Intorcia and O. Strom (2015). “Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis.” Osteoporos Int 26(10): 2401-2411.

Olafsson, G., E. Jonsson, P. Fritzell, O. Hagg and F. Borgstrom (2015). “Burden of Spinal Diseases: Results From Register Study In Sweden.” Value Health 18(7): A642.

Strom, O., E. Landfeldt and G. Garellick (2015). “Residual effect after oral bisphosphonate treatment and healthy adherer effects–the Swedish Adherence Register Analysis (SARA).” Osteoporos Int 26(1): 315-325.

Teitsson, S., J. Bobula, C. Hawes, M. Moffatt, A. Ohna and F. Borgstrom (2015). “Cost-Effectiveness of Conjugated Estrogens/Bazedoxifene for the Treatment of Vasomotor Symptoms in the United States.” Value Health 18(7): A736.

2014

Banefelt, J., A. Liede, J. Mesterton, J. Stalhammar, R. K. Hernandez, P. Sobocki and B. E. Persson (2014). “Survival and clinical metastases among prostate cancer patients treated with androgen deprivation therapy in Sweden.” Cancer Epidemiol.

Dimai, H. P., A. Svedbom, A. Fahrleitner-Pammer, H. Resch, C. Muschitz, H. Thaler, M. Szivak, K. Amrein and F. Borgstrom (2014). “Epidemiology of distal forearm fractures in Austria between 1989 and 2010.” Osteoporos Int 25(9): 2297-2306.

Henriksson, M., E. Nikolic, A. Ohna, L. Wallentin and M. Janzon (2014). “Ticagrelor treatment in patients with acute coronary syndrome is cost-effective in Sweden and Denmark.” Scand Cardiovasc J 48(3): 138-147.

Johnsen, L. G., C. Hellum, K. Storheim, O. P. Nygaard, J. I. Brox, I. Rossvoll, M. Ro, H. Andresen, S. Lydersen, O. Grundnes, M. Pedersen, G. Leivseth, G. Olafsson, F. Borgstrom and P. Fritzell (2014). “Cost-Effectiveness of Total Disc Replacement Versus Multidisciplinary Rehabilitation in Patients With Chronic Low Back Pain: A Norwegian Multicenter RCT.” Spine (Phila Pa 1976) 39(1): 23-32.

Pares-Badell, O., G. Barbaglia, P. Jerinic, A. Gustavsson, L. Salvador-Carulla and J. Alonso (2014). “Cost of disorders of the brain in Spain.” PLoS One 9(8): e105471.

Piscitelli, P., M. Brandi, H. Cawston, A. Gauthier, J. A. Kanis, J. Compston, F. Borgstrom, C. Cooper and E. McCloskey (2014). “Epidemiological burden of postmenopausal osteoporosis in Italy from 2010 to 2020: estimations from a disease model.” Calcif Tissue Int 95(5): 419-427.

Salaj, P., R. Kubes, P. Cetkovsky, I. Capova, M. Penka, P. Ovesna, J. Mesterton and P. Lindgren (2014). “Economic evaluation of rFVIIa high initial dose compared to rFVIIa standard initial dose in patients with haemophilia with inhibitors using the Czech HemoRec registry.” Thromb Res 133(2): 162-167.

Strom, O., E. Landfeldt and G. Garellick (2014). “Residual effect after oral bisphosphonate treatment and healthy adherer effects-the Swedish adherence register analysis (SARA).” Osteoporos Int.

2013

Borgstrom, F., I. Lekander, M. Ivergard, O. Strom, A. Svedbom, V. Alekna, M. L. Bianchi, P. Clark, M. D. Curiel, H. P. Dimai, M. Jurisson, R. Kallikorm, O. Lesnyak, E. McCloskey, E. Nassonov, K. M. Sanders, S. Silverman, M. Tamulaitiene, T. Thomas, A. N. Tosteson, B. Jonsson and J. A. Kanis (2013). “The International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS)–quality of life during the first 4 months after fracture.” Osteoporos Int 24(3): 811-823.

Borgstrom, F., G. Olafsson, O. Strom, J. B. Tillman, D. Wardlaw, S. Boonen and C. Miltenburger (2013). “The impact of different health dimensions on overall quality of life related to kyphoplasty and non-surgical management.” Osteoporos Int 24(7): 1991-1999.

Dimai, H. P., A. Svedbom, A. Fahrleitner-Pammer, T. Pieber, H. Resch, E. Zwettler, H. Thaler, M. Szivak, K. Amrein and F. Borgstrom (2013). “Epidemiology of proximal humeral fractures in Austria between 1989 and 2008.” Osteoporos Int 24(9): 2413-2421.

Gustavsson, A., J. Bjorkman, C. Ljungcrantz, A. Rhodin, M. Rivano-Fischer, K. F. Sjolund and C. Mannheimer (2013). “Pharmacological treatment patterns in neuropathic pain–lessons from Swedish administrative registries.” Pain Med 14(7): 1072-1080.

Hubschle, L., F. Borgstrom, G. Olafsson, C. Roder, P. Moulin, A. W. Popp, F. Kulling and E. Aghayev (2013). “Real-life results of balloon kyphoplasty for vertebral compression fractures from the SWISSspine registry.” Spine J.

Kanis, J. A., F. Borgstrom, J. Compston, K. Dreinhofer, E. Nolte, L. Jonsson, W. F. Lems, E. V. McCloskey, R. Rizzoli and J. Stenmark (2013). “SCOPE: a scorecard for osteoporosis in Europe.” Arch Osteoporos 8(1-2): 144.

Karampampa, K., A. Gustavsson, E. T. van Munster, R. M. Hupperts, E. A. Sanders, J. Mostert, O. L. Sinnige, J. de Graaf, P. Pop, C. Miltenburger, M. T. Groot, M. Relleke and W. S. van der Hel (2013). “Treatment experience, burden, and unmet needs (TRIBUNE) in Multiple Sclerosis study: the costs and utilities of MS patients in The Netherlands.” J Med Econ 16(7): 939-950.

Lekander, I., F. Borgstrom, J. Lysholm, R. F. van Vollenhoven, S. Lindblad, P. Geborek and G. Kobelt (2013). “The cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice.” Eur J Health Econ 14(6): 863-873.

Lekander, I., G. Kobelt, P. Svarvar, T. Ljung, R. van Vollenhoven and F. Borgstrom (2013). “The comparison of trial data-based and registry data-based cost-effectiveness of infliximab treatment for rheumatoid arthritis in Sweden using a modeling approach.” Value Health 16(2): 251-258.

Lindholm, C., A. Gustavsson, L. Jonsson and A. Wimo (2013). “Costs explained by function rather than diagnosis–results from the SNAC Nordanstig elderly cohort in Sweden.” Int J Geriatr Psychiatry 28(5): 454-462.

Strom, O., B. Jonsson and J. A. Kanis (2013). “Intervention thresholds for denosumab in the UK using a FRAX(R)-based cost-effectiveness analysis.” Osteoporos Int 24(4): 1491-1502.

Svedbom, A., L. Alvares, C. Cooper, D. Marsh and O. Strom (2013). “Balloon kyphoplasty compared to vertebroplasty and nonsurgical management in patients hospitalised with acute osteoporotic vertebral compression fracture: a UK cost-effectiveness analysis.” Osteoporos Int 24(1): 355-367.

2012

By, A., P. Sobocki, A. Forsgren and S. A. Silfverdal (2012). “Comparing health outcomes and costs of general vaccination with pneumococcal conjugate vaccines in Sweden: a Markov model.” Clin Ther 34(1): 177-189.

Cawston, H., M. Maravic, P. Fardellone, A. Gauthier, J. A. Kanis, J. Compston, F. Borgstrom, C. Cooper and E. McCloskey (2012). “Epidemiological burden of postmenopausal osteoporosis in France from 2010 to 2020: estimations from a disease model.” Arch Osteoporos.

Dimai, H. P., K. Redlich, M. Peretz, F. Borgstrom, U. Siebert and J. Mahlich (2012). “Economic burden of osteoporotic fractures in Austria.” Health Econ Rev 2(1): 12.

Gauthier, A., J. A. Kanis, Y. Jiang, K. Dreinhofer, M. Martin, J. Compston, F. Borgstrom, C. Cooper and E. McCloskey (2012). “Burden of postmenopausal osteoporosis in Germany: estimations from a disease model.” Arch Osteoporos.

Gustavsson, A., J. Bjorkman, C. Ljungcrantz, A. Rhodin, M. Rivano-Fischer, K. F. Sjolund and C. Mannheimer (2012). “Socio-economic burden of patients with a diagnosis related to chronic pain – Register data of 840,000 Swedish patients.” Eur J Pain 16(2): 289-299.

Gustavsson, A., J. Bjorkman, C. Ljungcrantz, A. Rhodin, M. Rivano-Fischer, K. F. Sjolund and C. Mannheimer (2012). “Pharmaceutical treatment patterns for patients with a diagnosis related to chronic pain initiating a slow-release strong opioid treatment in Sweden.” Pain 153(12): 2325-2331.

Johansson, E., A. Gustavsson, C. Miltenburger, K. Karampampa, L. Rumbach, K. Rerat and C. Thonnelier (2012). “Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from France.” Mult Scler 18(2 Suppl): 17-22.

Jonsson, B., O. Strom, J. A. Eisman, A. Papaioannou, E. S. Siris, A. Tosteson and J. A. Kanis (2012). “Comment on: Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis.” Osteoporos Int 23(7): 2063-2065.

Karampampa, K., A. Gustavsson, C. Miltenburger and B. Eckert (2012). “Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from five European countries.” Mult Scler 18(2 Suppl): 7-15.

Karampampa, K., A. Gustavsson, C. Miltenburger, C. M. Kindundu and D. H. Selchen (2012). “Treatment experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis: the costs and utilities of MS patients in Canada.” J Popul Ther Clin Pharmacol 19(1): e11-25.

Karampampa, K., A. Gustavsson, C. Miltenburger, S. Mora and T. Arbizu (2012). “Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from Spain.” Mult Scler 18(2 Suppl): 35-39.

Karampampa, K., A. Gustavsson, C. Miltenburger, K. Neidhardt and M. Lang (2012). “Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from Germany.” Mult Scler 18(2 Suppl): 23-27.

Karampampa, K., A. Gustavsson, C. Miltenburger, C. Teruzzi and G. Fattore (2012). “Treatment experience, burden and un